[Autophagy](/entities/autophagy)-lysosomal pathway dysfunction is a central mechanism underlying protein aggregation and neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. The autophagy-lysosomal system (ALS) is responsible for clearing damaged organelles, misfolded proteins, and protein aggregates. When this system fails, toxic protein species accumulate, leading to cellular dysfunction and death. [@menzies2019]
This integration page examines how autophagy and lysosomal function become impaired across neurodegenerative diseases, the consequences of this dysfunction, and therapeutic strategies targeting protein clearance pathways. The understanding of autophagy-lysosomal dysfunction has advanced significantly in recent years, with new therapeutic modalities emerging from basic research to clinical testing. [@auto_lysosome_2024]
The autophagy system encompasses several distinct pathways: [@schondorf2014]
Macroautophagy involves the formation of double-membraned autophagosomes that engulf cytoplasmic contents and fuse with lysosomes. This is the primary pathway for clearing large protein aggregates and damaged organelles. Macroautophagy can be selective (for specific cargo) or non-selective (bulk degradation). Key regulators include the ULK1 complex, Beclin-1, and the ATG5-12/ATG16L1 conjugation system. [@gao2019]
[Autophagy](/entities/autophagy)-lysosomal pathway dysfunction is a central mechanism underlying protein aggregation and neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. The autophagy-lysosomal system (ALS) is responsible for clearing damaged organelles, misfolded proteins, and protein aggregates. When this system fails, toxic protein species accumulate, leading to cellular dysfunction and death. [@menzies2019]
This integration page examines how autophagy and lysosomal function become impaired across neurodegenerative diseases, the consequences of this dysfunction, and therapeutic strategies targeting protein clearance pathways. The understanding of autophagy-lysosomal dysfunction has advanced significantly in recent years, with new therapeutic modalities emerging from basic research to clinical testing. [@auto_lysosome_2024]
The autophagy system encompasses several distinct pathways: [@schondorf2014]
Macroautophagy involves the formation of double-membraned autophagosomes that engulf cytoplasmic contents and fuse with lysosomes. This is the primary pathway for clearing large protein aggregates and damaged organelles. Macroautophagy can be selective (for specific cargo) or non-selective (bulk degradation). Key regulators include the ULK1 complex, Beclin-1, and the ATG5-12/ATG16L1 conjugation system. [@gao2019]
Microautophagy involves direct engulfment of cytoplasm by lysosomal membrane invagination. This process occurs at the lysosomal surface and is mediated by lysosomal membrane proteins. While less characterized than macroautophagy, microautophagy contributes to organelle quality control and may be particularly important for mitochondrial turnover. [@khandelwal2019]
Chaperone-mediated autophagy (CMA) selectively degrades proteins containing a KFERQ motif, mediated by Hsc70 and LAMP-2A. CMA is unique among autophagy pathways as it does not require membrane remodeling. Proteins are directly translocated across the lysosomal membrane via the LAMP-2A receptor. CMA is particularly important for degrading damaged or oxidized proteins and is impaired with aging. [@scrivo2018]
Mitophagy is the selective autophagy of mitochondria, critical for maintaining neuronal health. The PINK1-PARKIN pathway is the best-characterized mitophagy mechanism: upon mitochondrial damage, PINK1 accumulates on the outer mitochondrial membrane, phosphorylates ubiquitin and PARKIN, triggering recruitment of autophagy receptors (p62, OPTN, NDP52) that link mitochondria to the growing autophagosome. [@mitophagy_2024]
Lysosomes contain hydrolytic enzymes that degrade proteins, lipids, nucleic acids, and carbohydrates. Lysosomal function depends on: [@kocaturk2018]
Autophagy-lysosomal dysfunction is an early and prominent feature in AD: [@harms2017]
Autophagosome accumulation: Autophagic vacuoles accumulate in AD [neurons](/entities/neurons), particularly in dystrophic neurites surrounding amyloid plaques. This reflects impaired fusion with lysosomes rather than increased autophagosome formation. Electron microscopy studies reveal that up to 80% of neurons in AD brain contain numerous autophagic vacuoles, many containing undigested material. [@nixon2013]
Lysosomal depletion: Cathepsin D and other lysosomal enzymes are reduced in AD brain, impairing protein clearance. Cathepsin D activity is significantly decreased in AD hippocampus, and this reduction correlates with cognitive decline. [@cathepsin_2024]
Amyloid clearance: [Aβ](/proteins/amyloid-beta) is normally cleared via autophagy; dysfunction leads to Aβ accumulation. Both macroautophagy and CMA contribute to Aβ degradation. Impairment at any step leads to extracellular plaque formation. [@kocaturk2018]
[Tau](/proteins/tau) clearance: Impairment of autophagy contributes to tau accumulation and propagation. Tau is normally degraded by both autophagy and the proteasome; when autophagy fails, hyperphosphorylated tau accumulates as neurofibrillary tangles. [@menzies2019]
ApoE4 effect: APOE4 carriers show impaired autophagy in [astrocytes](/entities/astrocytes) and neurons, contributing to increased AD risk. ApoE4 has been shown to inhibit TFEB nuclear localization, reducing lysosomal biogenesis. [@scrivo2018]
Genes implicated in AD autophagy:
PD is strongly linked to autophagy-lysosomal dysfunction: [@schondorf2014]
[α-Synuclein](/proteins/alpha-synuclein) clearance: Autophagy is the primary pathway for clearing α-synuclein. Mutations affecting autophagy increase PD risk. Both macroautophagy and CMA degrade α-synuclein; CMA is particularly important for soluble α-synuclein, while macroautophagy clears larger aggregates. [@gba_2024]
Gaucher disease link: GBA1 mutations (causing Gaucher disease) are the strongest genetic risk factor for PD, linking lysosomal dysfunction to PD pathogenesis. GBA1 encodes glucocerebrosidase (GCase), which is essential for glycosphingolipid catabolism. GCase deficiency leads to accumulation of glucosylceramide, which stabilizes toxic α-syn oligomers and impairs lysosomal function. [@gba_2024]
PINK1/PARKIN pathway: Mitophagy defects lead to accumulation of dysfunctional mitochondria. PINK1 and PARKIN mutations cause early-onset PD, and both proteins are critical for mitochondrial quality control. Loss of mitophagy leads to increased oxidative stress and dopaminergic neuron death. [@mitophagy_2024]
Lysosomal membrane permeability: Early event in PD pathogenesis. Permeabilization releases cathepsins into the cytosol, triggering apoptosis and inflammasome activation. [@lysosomal_2024]
ATP13A2 (PARK9): Lysosomal ATPase whose mutations cause Kufor-Rakeh syndrome, a form of parkinsonism. ATP13A2 is critical for lysosomal acidification and metal ion transport. [@khandelwal2019]
Key genes in PD autophagy:
Autophagy dysfunction contributes to ALS pathogenesis: [@gao2019]
Protein aggregate clearance: Autophagy normally clears mutant SOD1, TDP-43, and FUS aggregates. Motor neurons are particularly vulnerable to aggregate accumulation due to their size and high metabolic demands. [@atg5_2024]
Motoneuron vulnerability: Motor neurons are particularly dependent on efficient autophagy. They have high protein turnover requirements and limited regenerative capacity. [@khandelwal2019]
[mTOR](/mechanisms/mtor-signaling-pathway) pathway: Altered signaling affects autophagic initiation. mTOR hyperactivity inhibits ULK1, reducing autophagy induction. [@mtor_independent_2024]
Lysosomal dysfunction: Impaired lysosomal acidification in ALS models. Lysosomal pH is elevated in SOD1 mutant mice, reducing cathepsin activity. [@lysosomal_2024]
C9orf72 DPRs: Dipeptide repeat proteins from C9orf72 expansion interfere with autophagy initiation and lysosomal function. [@scrivo2018]
Key genes in ALS autophagy:
mTOR inhibitors (activate autophagy by inhibiting mTORC1):
Enzyme enhancement:
| Compound | Target | Phase | Indication | Status |
|----------|--------|-------|------------|--------|
| Rapamycin | mTOR | Phase II | AD | Active |
| Everolimus | mTOR | Phase II | AD | Completed |
| Urolithin A | Mitophagy | Phase III | AD | Recruiting |
| Nicotinamide Riboside | NAD+/Mitophagy | Phase II | PD | Active |
| Genistein | Autophagy | Phase I/II | ALS | Active |
| Trehalose | Autophagy | Phase II | PD | Active |
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses:
The following diagram shows the key molecular relationships involving Autophagy-Lysosomal Dysfunction in Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis: